Patanjali Appeals HC Ban on Ads Criticizing Dabur Chyawanprash

Fast Summary

• Patanjali Ayurved has approached the Delhi High Court challenging an interim order restraining it from airing advertisements deemed disparaging to dabur Chyawanprash.
• A bench of Justices C. Hari Shankar and om Prakash Shukla observed that Patanjali’s ads seemingly constitute “generic disparagement,” referencing Dabur’s chyawanprash specifically through phrases like “ordinary chyawanprash made with 40 herbs.”
• The court warned against “luxury litigation” and stated costs would be imposed if the appeal appeared unnecessary or baseless. It questioned the irreparable harm claimed by Patanjali in appealing this discretionary order.
• On July 3, a single judge had issued an interim injunction on Dabur’s plea, requiring Patanjali to modify certain claims in its advertisements in both TV and print campaigns featuring yoga guru Ramdev.
• Dabur alleges that Patanjali’s ads falsely claim no other manufacturers understand Ayurvedic texts or readiness methods for chyawanprash, labeling their products as “ordinary” or “inferior.”
• Further hearings on this appeal have been scheduled for September 23, 2025.

Indian Opinion Analysis
This legal advancement highlights critical issues of competitive advertising practices between two major players in india’s FMCG sector using Ayurveda-based products: Patanjali and Dabur. Advertising can considerably influence consumer perception; however, when promotional strategies involve direct or indirect disparagement of competitors’ products-as argued by Dabur-it may erode trust within industries traditionally rooted in holistic wellness values like Ayurveda.

The warning by the Delhi High Court regarding potential misuse of appeals underscores judicial concerns about corporate litigations escalating unnecessarily, consuming resources without satisfying significant grievance criteria. This matter also reinforces how regulatory oversight is vital to ensure fair competition while preventing misinformation tied to health-related claims-an area especially sensitive given India’s sizable reliance on customary medicine markets.

As proceedings continue on September 23rd, consumers might anticipate ripple effects such as stricter advertising guidelines within similar product categories aimed at curtailing possible conflicts between competing businesses.For more details: Delhi HC restrains Patanjali from airing ‘disparaging’ ads against Dabur Chyawanprash